namilumab namilumab namilumab (alternative identifier mt203) is a human monoclonal antibody (class igg1 kappa) that targets granulocyte macrophage-colony stimulating factor (gm-csf)/colony stimulating factor 2 (csf2) and is currently being researched for application in rheumatoid arthritis (ra) and psoriatic arthritis. clinical trials investigating the therapeutic utility of namilumab have include phase i and phase ii clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis and rheumatoid arthritis. namilumabmonoclonal antibodytypewhole antibodysourcehumantargetcsf2clinical dataatc codenoneidentifierscas number1206681-39-1 nchemspidernoneuniimed485w763 ny (what is this?) (verify) namilumab was produced by micromet inc and is under development by takeda pharmaceuticals international.